Brookstone Capital Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,547
Closed -$376K 867
2022
Q3
$376K Buy
1,547
+15
+1% +$4.05K 0.01% 612
2022
Q2
$409K Sell
1,532
-92
-6% -$24.8K 0.01% 587
2022
Q1
$487K Sell
1,624
-23
-1% -$7.08K 0.01% 569
2021
Q4
$526K Sell
1,647
-45
-3% -$15.2K 0.01% 511
2021
Q3
$569K Buy
1,692
+2
+0.1% +$678 0.01% 477
2021
Q2
$539K Sell
1,690
-459
-21% -$141K 0.01% 467
2021
Q1
$685K Sell
2,149
-72
-3% -$23K 0.03% 304
2020
Q4
$720K Sell
2,221
-14,318
-87% -$3.96M 0.03% 282
2020
Q3
$4.58M Buy
16,539
+13,118
+383% +$3.78M 0.21% 72
2020
Q2
$826K Buy
3,421
+779
+29% +$156K 0.05% 182
2020
Q1
$384K Buy
2,642
+131
+5% +$21.7K 0.02% 237
2019
Q4
$428K Buy
2,511
+92
+4% +$17.1K 0.02% 296
2019
Q3
$430K Buy
2,419
+695
+40% +$150K 0.02% 290
2019
Q2
$449K Buy
1,724
+684
+66% +$181K 0.03% 298
2019
Q1
$297K Buy
1,040
+213
+26% +$70.8K 0.02% 332
2018
Q4
$269K Buy
827
+70
+9% +$24.3K 0.02% 240
2018
Q3
$340K Sell
757
-667
-47% -$263K 0.03% 317
2018
Q2
$582K Buy
1,424
+31
+2% +$11.2K 0.05% 183
2018
Q1
$405K Buy
+1,393
New +$353K 0.04% 227

Other funds holding ABMD

Brookstone Capital Management's ABMD Position: Q4 2022 in Review

Brookstone Capital Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,547 shares — an estimated $376K sold.

Brookstone Capital Management first reported a position in ABMD in Q1 2018 and held it in 19 quarters. The position peaked at $4.58M in Q3 2020. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Brookstone Capital Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Brookstone Capital Management sold 1,547 Abiomed Inc shares in Q4 2022, an estimated $376K.
  • Brookstone Capital Management first reported a position in Abiomed Inc in Q1 2018 and held it in 19 quarters.
  • Brookstone Capital Management's Abiomed Inc position peaked at $4.58M in Q3 2020.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Brookstone Capital Management's 13F filing for Q4 2022, filed 9 Jan 2023.